Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Oclusor do Apêndice Auricular Esquerdo LAmbre™ II e Sistema de Entrega do Oclusor para Pacientes com Fibrilhação Auricular Não Valvular (LAmbre2)

15 de setembro de 2026 atualizado por: Dr So Chak Yu kent, Prince of Wales Hospital, Shatin, Hong Kong

Um Estudo First-in-Man (FIM) do Oclusor de Apêndice Auricular Esquerdo LAmbre™ II e do Sistema de Entrega do Oclusor para Pacientes com Fibrilhação Auricular Não Valvular

Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds, and 6.7% ~17.9% among > 79 year-olds. Thromboembolic complications are the leading cause of death and disability in patients with AF, with ischemic stroke being the most common complication. AF significantly increases the risk of stroke by 3- to 5-fold due to thrombosis caused by abnormal atrial beat. The overall risk of ischemic stroke in patients with AF is 20% ~ 30%, and strokes due to atrial fibrillation account for 20% of all strokes.

In the current 2023 ACC/AHA/ACCP/HRS Guideline, percutaneous LAAC has been classified as a Class 2a indication for stroke prevention in patients with AF, a moderate to high risk of stroke, and a contraindication to long-term oral anticoagulation due to a nonreversible cause. However, the implantation procedure does have adverse effects which include serious pericardial effusion, procedure-related ischemic stroke, and device embolization. Due to the anatomical diversity of the LAA, certain patients are not candidates for this device.

The LAmbre™ Left Atrial Appendage Closure System, manufactured by Lifetech Scientific (Shenzhen) Co.Ltd., is the first generation of LAmbre LAAO device which is CE-marked and is current approved in Hong Kong Hospital Authority for regular clinical use. It consists of a LAA Occluder and a Delivery System and is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage in patients who have nonvalvular atrial fibrillation.

This self-expanding LAA Occluder consists of an umbrella and a cover connected by a central waist. Although the first generation of LAmbre LAAO device is associated with high implantation success rate of 99.7% and a relatively low major procedure-related complication rate of 2.9%, to better match the challenging anatomy of the LAA and to further improve procedural safety, the first generation of LAmbre LAAO device has been upgraded.

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation, is being evaluated in a prospective, single-center, single-arm First In Man (FIM) study. The study, conducted at the Prince of Wales Hospital, Chinese University of Hong Kong, aims to assess the preliminary safety and feasibility of the device and its Occluder Delivery System in 10 subjects who are at increased risk for stroke and systemic embolism, either due to their anticoagulation therapy eligibility or contraindications.

The enrollment period is expected to take approximately 6 months and subjects will have follow-up before discharge and at 30 days, 3M, 6M, 12M months post-operation. The total study duration is expected to be approximately 19 months.

Visão geral do estudo

Status

Ativo, não recrutando

Tipo de estudo

Intervencional

Inscrição (Estimado)

10

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Shatin, Hong Kong
        • The Chinese University of Hong Kong

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • The patient age ≥18 years;
  • The patient has documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;
  • The patient has a CHA2DS2-VASc score of ≥ 2 in men and CHA2DS2-VASc score of ≥ 3 in women;
  • The patient is recommended for oral anticoagulation therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation;
  • The patient is deemed suitable for LAA closure by the site investigator and a clinician not a part of the procedural team in the shared decision-making process, and this determination has been documented in the patient's medical record;
  • The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;
  • The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

  • 1. Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to the index procedure;
  • Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism);
  • Patients who require long-term anticoagulation for a condition other than atrial fibrillation;
  • Bleeding diathesis or coagulopathy;
  • Patients with rheumatic mitral valve disease, known severe mitral stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis;
  • Active infection with bacteremia;
  • Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and/or contrast sensitivity;
  • Prior atrial septal defect (ASD) or patient foramen ovale (PFO) surgical repair or implantation of closure device;
  • Left atrial appendage is obliterated and surgical ligated;
  • Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.);
  • Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;
  • New York Heart Association Class IV;
  • Patients with severe renal failure (estimated glomerular filtration rate<30 ml/min/1.73m2);
  • Known asymptomatic carotid artery disease with>70% diameter stenosis OR symptomatic carotid disease (>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is <50%;
  • Life expectancy is less than 1 year;
  • Current participation in another investigational drug or device study.

Echocardiographic Exclusion Criteria:

  • Left atrial appendage anatomy cannot accommodate the LAmbre II LAA Occluder per manufacturer IFU;
  • LVEF <30%;
  • Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE prior to implant;
  • Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length >15 mm) or large shunt (early, within 3 beats and/or substantial passage of 20 bubbles);
  • Existing circumferential pericardial effusion >5 mm;
  • Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2);
  • Complex atheroma with mobile plaque of the descending aorta and/or aortic arch;
  • Presence of a cardiac tumor

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Intervenção

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
LAA closure success rate
Prazo: 3 months post-procedure

complete LAA closure or peri-device residual leak ≤3 mm measured by TEE at 3 months post-procedure

3 months post-procedure
Procedural complication rate
Prazo: peri-procedure

Rate of complication rate peri-procedure

peri-procedure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Rate of death
Prazo: Perioperative

Rate of death at discharge

Perioperative
Rate of stroke
Prazo: Perioperative

Rate of stroke at discharge

Perioperative
Rate of stroke
Prazo: At 30 days post-OP

Rate of stroke at 30 days post-OP

At 30 days post-OP
Rate of stroke
Prazo: At 6 months post-OP

Rate of stroke at 6 months post-OP

At 6 months post-OP
Rate of stroke
Prazo: At 12 months post-OP

Rate of stroke at 12 months post-OP

At 12 months post-OP
Rate of systemic embolism
Prazo: Perioperative

Rate of systemic embolism at discharge

Perioperative
Rate of systemic embolism
Prazo: At 30 days post-OP

Rate of systemic embolism at 30 days post-OP

At 30 days post-OP
Rate of systemic embolism
Prazo: At 3 months post-OP

Rate of systemic embolism at 3 months post-OP

At 3 months post-OP
Rate of systemic embolism
Prazo: At 6 months post-OP

Rate of systemic embolism at 6 months post-OP

At 6 months post-OP
Rate of systemic embolism
Prazo: At 12 months post-OP

Rate of systemic embolism at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion with tamponade
Prazo: Perioperative

Rate of pericardial effusion with tamponade at discharge

Perioperative
Rate of pericardial effusion with tamponade
Prazo: At 30 days post-OP

Rate of pericardial effusion with tamponade at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion with tamponade
Prazo: At 3 months post-OP

Rate of pericardial effusion with tamponade at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion with tamponade
Prazo: At 6 months post-OP

Rate of pericardial effusion with tamponade at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion with tamponade
Prazo: At 12 months post-OP

Rate of pericardial effusion with tamponade at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion requiring drainage
Prazo: Perioperative

Rate of pericardial effusion requiring drainage at discharge

Perioperative
Rate of pericardial effusion requiring drainage
Prazo: At 30 days post-OP

Rate of pericardial effusion requiring drainage at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion requiring drainage
Prazo: At 3 months post-OP

Rate of pericardial effusion requiring drainage at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion requiring drainage
Prazo: At 6 months post-OP

Rate of pericardial effusion requiring drainage at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion requiring drainage
Prazo: At 12 months post-OP

Rate of pericardial effusion requiring drainage at 12 months post-OP

At 12 months post-OP
Rate of device embolization
Prazo: Perioperative

Rate of device embolization at discharge

Perioperative
Rate of device embolization
Prazo: At 30 days post-OP

Rate of device embolization at discharge at 30 days post-OP

At 30 days post-OP
Rate of device embolization
Prazo: At 3 months post-OP

Rate of device embolization at 3 months post-OP

At 3 months post-OP
Rate of death
Prazo: At 30 days

Rate of death at 30 days

At 30 days
Rate of death
Prazo: At 3 months post-OP

Rate of death at 3 months post-OP

At 3 months post-OP
Rate of death
Prazo: At 6 months post-OP

Rate of death at 6 months post-OP

At 6 months post-OP
Rate of death
Prazo: At 12 months post-OP

Rate of death at 12 months post-OP

At 12 months post-OP
Rate of device embolization
Prazo: At 6 months post-OP

Rate of device embolization at 6 months post-OP

At 6 months post-OP
Rate of device embolization
Prazo: At 12 months post-OP

Rate of device embolization at 12 months post-OP

At 12 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Prazo: Perioperative

Rate of major bleeding (BARC defined 3 to 5) at discharge

Perioperative
Rate of major bleeding (BARC defined 3 to 5)
Prazo: At 30 days post-OP

Rate of major bleeding (BARC defined 3 to 5) at 30 days post-OP

At 30 days post-OP
Rate of major bleeding (BARC defined 3 to 5)
Prazo: At 3 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 3 months post-OP

At 3 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Prazo: At 6 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 6 months post-OP

At 6 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Prazo: At 12 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 12 months post-OP

At 12 months post-OP
Closure success assessed by TEE or cardiac computed tomography
Prazo: At 30 days post-procedure

Closure success assessed by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Closure success assessed by TEE or cardiac computed tomography
Prazo: At 6 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Closure success assessed by TEE or cardiac computed tomography
Prazo: At 12 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure
Rate of minor bleeding (BARC type 2)
Prazo: At discharge, 30 days and 3, 6, 12 months post-procedure

Rate of minor bleeding (BARC type 2) at discharge

At discharge, 30 days and 3, 6, 12 months post-procedure
Rate of minor bleeding (BARC type 2)
Prazo: At 30 days post-procedure

Rate of minor bleeding (BARC type 2) at 30 days post-procedure

At 30 days post-procedure
Rate of minor bleeding (BARC type 2)
Prazo: At 3 months post-procedure

Rate of minor bleeding (BARC type 2) at 3 months post-procedure

At 3 months post-procedure
Rate of minor bleeding (BARC type 2)
Prazo: At 6 months post-procedure

Rate of minor bleeding (BARC type 2) at 6 months post-procedure

At 6 months post-procedure
Rate of minor bleeding (BARC type 2)
Prazo: At 12 months post-procedure

Rate of minor bleeding (BARC type 2) at 12 months post-procedure

At 12 months post-procedure
Rate of cardiovascular death
Prazo: Perioperative

Rate of cardiovascular death at discharge

Perioperative
Rate of cardiovascular death
Prazo: At 30 days post-procedure

Rate of cardiovascular death at 30 days post-procedure.

At 30 days post-procedure
Rate of cardiovascular death
Prazo: At 3 months post-procedure

Rate of cardiovascular death at 3 months post-procedure.

At 3 months post-procedure
Rate of cardiovascular death
Prazo: At 6 months post-procedure

Rate of cardiovascular death at 6 months post-procedure.

At 6 months post-procedure
Rate of cardiovascular death
Prazo: At 12 months post-procedure

Rate of cardiovascular death at 12 months post-procedure.

At 12 months post-procedure
Rate of ischemic stroke
Prazo: Perioperative

Rate of ischemic stroke at discharge

Perioperative
Rate of ischemic stroke
Prazo: At 30 days post-procedure

Rate of ischemic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of ischemic stroke
Prazo: At 3 months post-procedure

Rate of ischemic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of ischemic stroke
Prazo: At 6 months post-procedure

Rate of ischemic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of ischemic stroke
Prazo: At 12 months post-procedure

Rate of ischemic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of hemorrhagic stroke
Prazo: Perioperative

Rate of hemorrhagic stroke at discharge

Perioperative
Rate of hemorrhagic stroke
Prazo: At 30 days post-procedure

Rate of hemorrhagic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of hemorrhagic stroke
Prazo: At 3 months post-procedure

Rate of hemorrhagic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of hemorrhagic stroke
Prazo: At 6 months post-procedure

Rate of hemorrhagic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of hemorrhagic stroke
Prazo: At 12 months post-procedure

Rate of hemorrhagic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of systemic embolization
Prazo: Perioperative

Rate of systemic embolization at discharge

Perioperative
Rate of systemic embolization
Prazo: At 30 days post-procedure

Rate of systemic embolization at 30 days post-procedure

At 30 days post-procedure
Rate of systemic embolization
Prazo: At 3 months post-procedure

Rate of systemic embolization at 3 months post-procedure

At 3 months post-procedure
Rate of systemic embolization
Prazo: At 6 months post-procedure

Rate of systemic embolization at 6 months post-procedure

At 6 months post-procedure
Rate of systemic embolization
Prazo: At 12 months post-procedure

Rate of systemic embolization at 12 months post-procedure

At 12 months post-procedure
Procedural Technical success rate
Prazo: During procedure

Procedural Technical success rate, defined as successful delivery and release of study device with acceptable device position and stability, and closure success;

During procedure
Procedural success rate
Prazo: Peri-procedure

Procedural success rate, defined as technical success without major peri-procedural complications

Peri-procedure
Rate of Device-related thrombosis
Prazo: At 30 days post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Rate of Device-related thrombosis
Prazo: At 3 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 3 months post-procedure

At 3 months post-procedure
Rate of Device-related thrombosis
Prazo: At 6 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Rate of Device-related thrombosis
Prazo: At 12 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

5 de março de 2026

Conclusão Primária (Estimado)

1 de novembro de 2027

Conclusão do estudo (Estimado)

1 de maio de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

25 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de março de 2026

Primeira postagem (Real)

6 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever